HomeClinical TopicsFDA approves hepatitis C drugs for pediatric patients

FDA approves hepatitis C drugs for pediatric patients

On April 7, the U.S. Food and Drug Administration (FDA) approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Women suffering from a migraine

Quiz: Migraines and Hormones

Women are 2 to 3 times more likely than men to have migraines.  Decades ago, these were attributed to women’s inability to cope with...